TREA

79232578 - HYFC TECHNOLOGY

Follow

Information

  • Trademark
  • 79232578
  • Serial Number
    79232578
  • Registration Number
    5736165
  • Filing Date
    February 28, 2018
    6 years ago
  • Registration Date
    April 30, 2019
    5 years ago
  • Transaction Date
    April 30, 2024
    6 months ago
  • Status Date
    April 30, 2019
    5 years ago
  • Published for Opposition Date
    February 12, 2019
    5 years ago
  • Location Date
    April 30, 2019
    5 years ago
  • Status Code
    700
  • Current Location
    PUBLICATION AND ISSUE SECTION
    Employee Name
    EISNACH, MICHAEL PATRI
  • Law Office Assigned Location Code
    L40
  • Owners
Information
Mark Drawing Code
3
Mark Identification
HYFC TECHNOLOGY
Case File Statements
  • DM0000: The mark consists of a stylized design consisting of two ovals connected by 5 lines to two more ovals that are divided, and are stacked above two other ovals. To the right of the stylized design are the letters "hyFc" stacked above the word "technology".
  • GS0051: Pharmaceutical products for the treatment of infectious diseases; pharmaceutical preparations for treating hypertension; pharmaceutical preparations for the prevention of osteoporosis; pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for treating diabetes; pharmaceutical agents affecting metabolism; pharmaceutical preparations for regulating the immune system; pharmaceutical products for the treatment of viral diseases; pharmaceutical preparations for urogenital organs; pharmaceutical preparations for preventing and treating obesity; pharmaceutical products for the treatment of bone diseases; pharmaceutical preparations for wounds; pharmaceutical preparations for activating cellular function; pharmaceutical agents affecting digestive organs; cardiovascular pharmaceutical preparations; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for treating malignant tumours; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; pharmaceutical preparations for the treatment of cancer; Synthetic peptides for pharmaceutical purposes for the treatment of infectious diseases; Synthetic peptides for pharmaceutical purposes for treating hypertension; Synthetic peptides for pharmaceutical purposes for the prevention of osteoporosis; Synthetic peptides for pharmaceutical purposes for the treatment of hormonal disorders and the prevention of osteoporosis; Synthetic peptides for pharmaceutical purposes for the treatment of eye diseases and conditions; Synthetic peptides for pharmaceutical purposes for the treatment of multiple sclerosis; Synthetic peptides for pharmaceutical purposes for treating diabetes; Synthetic peptides for pharmaceutical purposes for affecting metabolism; Synthetic peptides for pharmaceutical purposes for regulating the immune system; Synthetic peptides for pharmaceutical purposes for the treatment of viral diseases; Synthetic peptides for pharmaceutical purposes for affecting and treating urogenital organs; Synthetic peptides for pharmaceutical purposes for preventing and treating obesity; Synthetic peptides for pharmaceutical purposes for the treatment of bone diseases; Synthetic peptides for pharmaceutical purposes for wounds; Synthetic peptides for pharmaceutical purposes for activating cellular function; Synthetic peptides for pharmaceutical purposes for affecting digestive organs; Synthetic peptides for pharmaceutical purposes for the treatment of cardiovascular disease; Synthetic peptides for pharmaceutical purposes for treating malignant tumours; Synthetic peptides for pharmaceutical purposes for the treatment and prevention of cancer; Synthetic peptides for pharmaceutical purposes for treatment of viral and infectious diseases, for the treatment of cancer; Synthetic peptides for pharmaceutical purposes for the treatment of cancer; Synthetic peptides for pharmaceutical purposes for the treatment of auto-immune diseases; pharmaceutical preparations for the treatment of auto-immune diseases
  • CC0000: Color is not claimed as a feature of the mark.
  • DS0000: "TECHNOLOGY"
Case File Event Statements
  • 6/12/2018 - 6 years ago
    4 - ASSIGNED TO EXAMINER Type: DOCK
  • 5/24/2018 - 6 years ago
    1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR
  • 6/1/2018 - 6 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 6/5/2018 - 6 years ago
    3 - APPLICATION FILING RECEIPT MAILED Type: MAFR
  • 6/19/2018 - 6 years ago
    5 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 6/20/2018 - 6 years ago
    6 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR
  • 6/28/2018 - 6 years ago
    7 - REFUSAL PROCESSED BY MPU Type: RFRR
  • 6/28/2018 - 6 years ago
    8 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS
  • 12/27/2018 - 5 years ago
    14 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA
  • 12/27/2018 - 5 years ago
    10 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 1/23/2019 - 5 years ago
    15 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 1/23/2019 - 5 years ago
    16 - NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Type: OP2R
  • 1/23/2019 - 5 years ago
    17 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS
  • 2/8/2019 - 5 years ago
    18 - NOTIFICATION PROCESSED BY IB Type: GPNX
  • 7/14/2018 - 6 years ago
    9 - REFUSAL PROCESSED BY IB Type: RFNT
  • 12/27/2018 - 5 years ago
    11 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 12/27/2018 - 5 years ago
    12 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 12/28/2018 - 5 years ago
    13 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 2/12/2019 - 5 years ago
    19 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 2/12/2019 - 5 years ago
    20 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 4/30/2019 - 5 years ago
    21 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 7/30/2019 - 5 years ago
    23 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Type: FICR
  • 8/24/2019 - 5 years ago
    24 - FINAL DISPOSITION PROCESSED Type: FIMP
  • 5/13/2019 - 5 years ago
    22 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA
  • 8/24/2019 - 5 years ago
    25 - FINAL DISPOSITION NOTICE SENT TO IB Type: FICS
  • 9/13/2019 - 5 years ago
    26 - FINAL DECISION TRANSACTION PROCESSED BY IB Type: FINO
  • 4/30/2024 - 6 months ago
    28 - COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED Type: REM3
  • 5/28/2020 - 4 years ago
    27 - NEW REPRESENTATIVE AT IB RECEIVED Type: NREP